
---
title: '新的疫苗类型克服癌症肿瘤防御'
categories: 
 - 新媒体
 - 科学网
 - 博客
headimg: 'https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202205/30/152231wq39jj3ctqk39tvj.jpg'
author: 科学网
comments: false
date: Mon, 30 May 2022 15:26:00 GMT
thumbnail: 'https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202205/30/152231wq39jj3ctqk39tvj.jpg'
---

<div>   
<p style="line-height: 3em;"><span style="font-family: "times new roman"; font-size: 24px;">新的疫苗类型克服癌症肿瘤防御</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">诸平</span></p><p style="text-align:center"><img src="https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202205/30/152231wq39jj3ctqk39tvj.jpg" title alt="vaccine-10.jpg" width="464" height="295" style="width: 464px; height: 295px;" referrerpolicy="no-referrer"><br></p><p style="line-height: 2em; text-align: center;"><span style="font-size: 18px; font-family: "times new roman";">Credit: Pixabay/CC0 Public Domain</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">据“医学快讯”网（</span><a href="https://medicalxpress.com/news/2022-05-vaccine-cancerous-tumor-defenses.html" target="_self"><span style="font-size: 18px; font-family: "times new roman";">Medical Xpress</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">）</span>2022<span style="font-size: 18px; font-family: 宋体;">年</span>5<span style="font-size: 18px; font-family: 宋体;">月</span>26<span style="font-size: 18px; font-family: 宋体;">日报道</span>,<span style="font-size: 18px; font-family: 宋体;">新的疫苗类型克服癌症肿瘤防御（</span></span><a href="https://medicalxpress.com/news/2022-05-vaccine-cancerous-tumor-defenses.html" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">New vaccine type overcomes cancerous tumor defenses</span></a><span style="font-size: 18px; font-family: "times new roman";">），为癌症患者治疗带来新希望。</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">美国多家研究所和日本一所研究所的研究团队开发出了一种可以克服免疫系统的防御系统，帮助消灭癌症肿瘤的新型疫苗。相关研究结果于</span>2022<span style="font-size: 18px; font-family: 宋体;">年</span>5<span style="font-size: 18px; font-family: 宋体;">月</span>25<span style="font-size: 18px; font-family: 宋体;">日已经在《自然》（</span></span><a href="https://dx.doi.org/10.1038/s41586-022-04772-4" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Nature</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">）杂志网站发表——</span>Soumya Badrinath, Maxence O. Dellacherie, Aileen Li, Shiwei Zheng, Xixi Zhang, Miguel Sobral, Jason W. Pyrdol, Kathryn L. Smith, Yuheng Lu, Sabrina Haag, Hamza Ijaz, Fawn Connor-Stroud, Tsuneyasu Kaisho, Glenn Dranoff, Guo-Cheng Yuan, David J. Mooney, Kai W. Wucherpfennig. A vaccine targeting resistant tumours by dual T cell plus NK cell attack. </span><a href="https://dx.doi.org/10.1038/s41586-022-04772-4" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Nature</span></a><span style="font-size: 18px; font-family: "times new roman";">, 2022. DOI: </span><a href="https://dx.doi.org/10.1038/s41586-022-04772-4" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">10.1038/s41586-022-04772-4</span></a><span style="font-size: 18px; font-family: "times new roman";">. Published: 25 May 2022. </span><a href="https://dx.doi.org/10.1038/s41586-022-04772-4" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">https://dx.doi.org/10.1038/s41586-022-04772-4</span></a><span style="font-size: 18px; font-family: "times new roman";">. <span style="font-size: 18px; font-family: 宋体;">在此论文中，该小组描述了这种新疫苗及其在小鼠（</span>mouse<span style="font-size: 18px; font-family: 宋体;">）和恒河猴（</span>rhesus macaque<span style="font-size: 18px; font-family: 宋体;">）模型中的效果。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">直到最近，医生治疗癌症患者（</span><a href="https://medicalxpress.com/tags/cancer+patients/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">cancer patients</span></a><span style="font-size: 18px; font-family: "times new roman";">）的唯一工具是化疗、放疗和手术。最近，医学研究人员（</span><a href="https://medicalxpress.com/tags/medical+researchers/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">medical researchers</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">）一直在探索对抗癌症的疫苗——例如，针对</span>HPV<span style="font-size: 18px; font-family: 宋体;">相关疾病的疫苗的开发已经降低了宫颈癌和其他类型癌症的风险。其他的研究工作包括针对肽抗原（</span>peptide antigens<span style="font-size: 18px; font-family: 宋体;">），并已被证明是有效的，但只在有限的情况下。在这项新的努力中，研究人员开发了一种更广泛的疫苗，他们相信可以用于多种癌症患者的多种癌症。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">这种新疫苗的工作原理是消除肿瘤使用的一种主要防御策略，即从其表面分裂</span>T<span style="font-size: 18px; font-family: 宋体;">细胞和自然杀伤细胞（</span></span><a href="https://medicalxpress.com/tags/natural+killer+cells/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">natural killer cells</span></a><span style="font-size: 18px; font-family: "times new roman";">）的能力。当身体检测到肿瘤生长时，就会部署这种细胞，并向免疫系统（</span><a href="https://medicalxpress.com/tags/immune+system/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">immune system</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">）发出警报。它们附着在表面的</span>MICA<span style="font-size: 18px; font-family: 宋体;">蛋白和</span>MICB<span style="font-size: 18px; font-family: 宋体;">蛋白上后脱落，肿瘤就可以自由生长。这种新疫苗通过干预肿瘤的分裂过程来发挥作用，阻止被派去杀死肿瘤的免疫细胞脱落。这种疫苗通过增加肿瘤细胞表面蛋白质的密度来破坏这种分裂过程，研究人员将其描述为“激发保护性免疫（</span>inciting protective immunity<span style="font-size: 18px; font-family: 宋体;">）”。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">迄今为止，该疫苗已在小鼠和恒河猴模型中证明是安全有效的。研究人员指出，有迹象表明，这种疫苗与放疗结合使用时效果更好。他们现在正在设计一项临床试验，将在人类身上测试这种新疫苗。</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">上述介绍，仅供参考。欲了解更多信息，敬请注意浏览</span><a href="https://dx.doi.org/10.1038/s41586-022-04772-4" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">原文</span></a><span style="font-size: 18px; font-family: "times new roman";">或者</span><a href="https://medicalxpress.com/news/2022-05-vaccine-cancerous-tumor-defenses.html" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">相关报道</span></a><span style="font-size: 18px; font-family: "times new roman";">。</span></p><p style="line-height: 2em;"><a href="https://medicalxpress.com/news/2022-05-vaccine-protein-effective-cancers-animals.html" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">针对一种在几种动物身上被发现的蛋白质的疫苗对多种癌症有效</span></a><span style="font-size: 18px; font-family: "times new roman";">（</span><a href="https://medicalxpress.com/news/2022-05-vaccine-protein-effective-cancers-animals.html" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Vaccine targeting a protein found to be effective against many types of cancers in several animals</span></a><span style="font-size: 18px; font-family: "times new roman";">）</span></p><p style="line-height: 2em;"><a href="https://dx.doi.org/10.1038/s41586-022-04772-4" style="text-decoration: underline; font-size: 18px; font-family: "arial black", "avant garde";" target="_blank"><span style="font-size: 18px; font-family: "arial black", "avant garde";">Abstract</span></a></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-family: "times new roman"; font-size: 18px; color: #222222; background: white;">Most cancer vaccines target peptide antigens, necessitating personalization owing to the vast inter-individual diversity in major histocompatibility complex (MHC) molecules that present peptides to T cells. Furthermore, tumours frequently escape T cell-mediated immunity through mechanisms that interfere with peptide presentation</span><sup style="box-sizing: inherit"><a href="https://www.nature.com/articles/s41586-022-04772-4#ref-CR1" title="Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707–723 (2017)." style="overflow-wrap: break-word;box-sizing: inherit" target="_blank"><span style="font-family: "times new roman"; font-size: 18px; color: #006699;">1</span></a></sup>. Here we report a cancer vaccine that induces a coordinated attack by diverse T cell and natural killer (NK) cell populations. The vaccine targets the MICA and MICB (MICA/B) stress proteins expressed by many human cancers as a result of DNA damage<sup style="box-sizing: inherit"><a href="https://www.nature.com/articles/s41586-022-04772-4#ref-CR2" title="Gasser, S., Orsulic, S., Brown, E. J. & Raulet, D. H. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436, 1186–1190 (2005)." style="overflow-wrap: break-word;box-sizing: inherit" target="_blank"><span style="font-family: "times new roman"; font-size: 18px; color: #006699;">2</span></a></sup>. MICA/B serve as ligands for the activating NKG2D receptor on T cells and NK cells, but tumours evade immune recognition by proteolytic MICA/B cleavage<sup style="box-sizing: inherit"><a href="https://www.nature.com/articles/s41586-022-04772-4#ref-CR3" title="Lanier, L. L. NKG2D receptor and its ligands in host defense. Cancer Immunol. Res. 3, 575–582 (2015)." style="overflow-wrap: break-word;box-sizing: inherit" target="_blank"><span style="font-family: "times new roman"; font-size: 18px; color: #006699;">3</span></a>,<a href="https://www.nature.com/articles/s41586-022-04772-4#ref-CR4" title="Kaiser, B. K. et al. Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature 447, 482–486 (2007)." style="overflow-wrap: break-word;box-sizing: inherit" target="_blank"><span style="font-family: "times new roman"; font-size: 18px; color: #006699;">4</span></a></sup>. Vaccine-induced antibodies increase the density of MICA/B proteins on the surface of tumour cells by inhibiting proteolytic shedding, enhance presentation of tumour antigens by dendritic cells to T cells and augment the cytotoxic function of NK cells. Notably, this vaccine maintains efficacy against MHC class I-deficient tumours resistant to cytotoxic T cells through the coordinated action of NK cells and CD4<sup style="box-sizing: inherit">+</sup> T cells. The vaccine is also efficacious in a clinically important setting: immunization following surgical removal of primary, highly metastatic tumours inhibits the later outgrowth of metastases. This vaccine design enables protective immunity even against tumours with common escape mutations.</span></p>                    <br><br>
                                        <label style="font-size:13px; color:#850f0f">转载本文请联系原作者获取授权，同时请注明本文来自诸平科学网博客。<br>链接地址：</label><a href="https://blog.sciencenet.cn/blog-212210-1340850.html" target="_blank" style="font-size:13px; color:#850f0f">https://blog.sciencenet.cn/blog-212210-1340850.html </a>
  <br><br>上一篇：<a href="http://blog.sciencenet.cn/blog-212210-1340704.html" target="_black">用微小粒子制造材料的新途径</a><br>                    <!--大赛结束-->
                                        
  
</div>
            